Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IBIO Bird Flu spreading again Everywhere
South Korea culls 26 million chickens to contain bird flu outbreak http://sabahdai.ly/hBuNoG
H5N8 bird flu strain discovered in farms in Cloppenburg in Germany's Lower Saxony http://www.dw.com/p/2UtOL?tw
Greece reports H5N8 bird flu in wild swan: OIE http://reut.rs/2iw1HCV
Bird flu kills two people in China: Authorities http://cnb.cx/2i26BLC
China's Suzhou city to halt live poultry trade on bird flu concerns http://reut.rs/2hdxlnG
BIRD FLU OUTBREAK: Health alert as wild birds across UK test POSITIVE for virus http://shr.gs/2RtO1Ej
BBC News - First case of wild bird flu in England confirmed in Leicestershire and Somerset http://www.bbc.com/news/uk-england-leicestershire-38421337
E China city halts live poultry trade amid bird flu concerns http://www.shanghaidaily.com/nation/E-China-city-halts-live-poultry-trade-amid-bird-flu-concerns/shdaily.shtml#jtss-twitter
$IBIO Bird Flu spreading again Everywhere
South Korea culls 26 million chickens to contain bird flu outbreak http://sabahdai.ly/hBuNoG
H5N8 bird flu strain discovered in farms in Cloppenburg in Germany's Lower Saxony http://www.dw.com/p/2UtOL?tw
Greece reports H5N8 bird flu in wild swan: OIE http://reut.rs/2iw1HCV
Bird flu kills two people in China: Authorities http://cnb.cx/2i26BLC
China's Suzhou city to halt live poultry trade on bird flu concerns http://reut.rs/2hdxlnG
BIRD FLU OUTBREAK: Health alert as wild birds across UK test POSITIVE for virus http://shr.gs/2RtO1Ej
BBC News - First case of wild bird flu in England confirmed in Leicestershire and Somerset http://www.bbc.com/news/uk-england-leicestershire-38421337
E China city halts live poultry trade amid bird flu concerns http://www.shanghaidaily.com/nation/E-China-city-halts-live-poultry-trade-amid-bird-flu-concerns/shdaily.shtml#jtss-twitter
$ALQA as well have Dr. Jerome Zeldis the former Chief Medical Officer of Celgene Corporation $CELG as current Chairman of the Board of Directors of Alliqua
https://alliqua.com/about-us/board-of-directors/
as well $ALQA has collaboration partenrship with $CELG Celgene for Biovance
$ALQA Biovance® Estimated Completion Date is December 2016 for Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers https://clinicaltrials.gov/ct2/show/NCT02506452 $ALQA has partenrship $CELG Biovance
$CBLI like here 1.60 and Russia as well as catalyst as things become more favorable
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "The side-by-side analytical comparability analysis of two formulations of entolimod is on schedule to be completed in the fourth quarter of 2016. Once we have this data and once the FDA has finalized the biocomparability study design, the biocomparability study in non-human primates ("NHP") may commence. We expect the NHP study will require approximately 6 months to complete, and we will update guidance on this point after the FDA has completed its reviews and our vendors have confirmed timing."
"In addition, we are in ongoing discussions with the European Medicines Agency ("EMA") for a pediatric investigational plan ("PIP") for entolimod as a medical radiation countermeasure. A proposed PIP was filed with the EMA. The EMA requires an agreement on a PIP with the sponsor as a prerequisite to filing a Marketing Authorization Application ("MAA"). We cannot currently estimate when an agreement on the PIP will be reached or if any additional studies will be required for an MAA submission."
"Clinical oncology studies with entolimod, CBLB612 and Mobilan are progressing in the Russian Federation," added Dr. Kogan. "Recruitment was completed in a Phase 2 study of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer and a Phase 2 study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The data from these studies are being analyzed. Panacela Labs is now dosing Mobilan in two dose-escalation Phase 1 studies evaluating single and double injection regimens administered directly into the prostate of patients with prostate cancer. All of these studies are supported by development contracts with the Russian Federation Ministry of Industry and Trade."
$CBLI like here 1.60 and Russia as well as catalyst as things become more favorable
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "The side-by-side analytical comparability analysis of two formulations of entolimod is on schedule to be completed in the fourth quarter of 2016. Once we have this data and once the FDA has finalized the biocomparability study design, the biocomparability study in non-human primates ("NHP") may commence. We expect the NHP study will require approximately 6 months to complete, and we will update guidance on this point after the FDA has completed its reviews and our vendors have confirmed timing."
"In addition, we are in ongoing discussions with the European Medicines Agency ("EMA") for a pediatric investigational plan ("PIP") for entolimod as a medical radiation countermeasure. A proposed PIP was filed with the EMA. The EMA requires an agreement on a PIP with the sponsor as a prerequisite to filing a Marketing Authorization Application ("MAA"). We cannot currently estimate when an agreement on the PIP will be reached or if any additional studies will be required for an MAA submission."
"Clinical oncology studies with entolimod, CBLB612 and Mobilan are progressing in the Russian Federation," added Dr. Kogan. "Recruitment was completed in a Phase 2 study of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer and a Phase 2 study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The data from these studies are being analyzed. Panacela Labs is now dosing Mobilan in two dose-escalation Phase 1 studies evaluating single and double injection regimens administered directly into the prostate of patients with prostate cancer. All of these studies are supported by development contracts with the Russian Federation Ministry of Industry and Trade."
$GEVO EnergyTechInvestor.com Discusses Alcohol-to-Jet Fuel (ATJ) with GEVO CEO Patrick R. Gruber http://www.marketwired.com/press-release/-2180056.htm
Gevo's Biofuels Fuel Growth Aided by EPA (GEVO) http://www.investopedia.com/news/gevos-biofuels-fuel-growth-aided-epa-gevo?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons via @investopedia
In the most recent 13F filings with the SEC, a total of 18 institutional investors and hedge funds increased their positions in Gevo stock, with a further 8 taking new positions.
Gevo partners with Musket Corp., brings isobutanol to the West http://boatingindustry.com/top-stories/2016/11/30/gevo-partners-with-musket-corp-brings-isobutanol-to-the-west/
$GEVO Alaska Airlines runs flight using fuel made from residual biomass http://www.renewableenergymagazine.com/biofuels/alaska-airlines-runs-flight-using-fuel-made-20161117
$GEVO The EPA has issued regulations requiring that the amount of biofuels blended into the U.S. fuel supply must increase by 6% throughout 2017.
$GEVO EnergyTechInvestor.com Discusses Alcohol-to-Jet Fuel (ATJ) with GEVO CEO Patrick R. Gruber http://www.marketwired.com/press-release/-2180056.htm
Gevo's Biofuels Fuel Growth Aided by EPA (GEVO) http://www.investopedia.com/news/gevos-biofuels-fuel-growth-aided-epa-gevo?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons via @investopedia
In the most recent 13F filings with the SEC, a total of 18 institutional investors and hedge funds increased their positions in Gevo stock, with a further 8 taking new positions.
Gevo partners with Musket Corp., brings isobutanol to the West http://boatingindustry.com/top-stories/2016/11/30/gevo-partners-with-musket-corp-brings-isobutanol-to-the-west/
$GEVO Alaska Airlines runs flight using fuel made from residual biomass http://www.renewableenergymagazine.com/biofuels/alaska-airlines-runs-flight-using-fuel-made-20161117
$GEVO The EPA has issued regulations requiring that the amount of biofuels blended into the U.S. fuel supply must increase by 6% throughout 2017.
$CYTX Cytori Publishes 2-Year Data in Scleroderma Trial of Cell Therapy http://sclerodermanews.com/2016/12/01/cytori-publishes-two-year-data-scleroderma-trial-cell-therapy via @sclerodermanews
$CERU .73 now with 1.35 in Cash and has announced recent five-target collaboration with Novartis received payment $5 million plus funding for five full-time equivalents and is eligible for milestone payments plus sales royalties for each target
http://files.shareholder.com/downloads/AMDA-2PIT2J/3308422877x0x912458/70869586-D91F-4F36-A76A-F9D833FB1660/CERU_News_2016_10_19_General_Releases.pdf
Roth Capital affirms Cerulean Pharma (Nasdaq: CERU) with a Buy rating and $2.50 price target following a new collaboration with Novartis and cash infusion
http://www.streetinsider.com/Analyst+Comments/Roth+Capital+Keeps+Cerulean+Pharma+(CERU)+at+Buy+Amid+Capital+Raise,+Key+Collaboration+with+Novartis/12146027.html
Cerulean also is eligible to receive preclinical, clinical, regulatory, and sales milestones for each of the five targets of up to $233 million per target.
http://finance.yahoo.com/news/cerulean-reports-third-quarter-2016-201100941.html
During 2017, Cerulean expects to:
Report further results from the ongoing Phase 1b/2 clinical trial of CRLX101 in combination with weekly paclitaxel, in patients with platinum-resistant ovarian cancer
Report initial results from the ongoing Phase 1/2 clinical trial of CRLX101 in combination with AstraZeneca’s PARP inhibitor, LYNPARZA, in patients with advanced solid tumors
Report initial results from the ongoing Phase 1/2a clinical trial of CRLX301 using a weekly dosing schedule in patients with advanced solid tumors
$CERU .73 now with 1.35 in Cash and has announced recent five-target collaboration with Novartis received payment $5 million plus funding for five full-time equivalents and is eligible for milestone payments plus sales royalties for each target
http://files.shareholder.com/downloads/AMDA-2PIT2J/3308422877x0x912458/70869586-D91F-4F36-A76A-F9D833FB1660/CERU_News_2016_10_19_General_Releases.pdf
Roth Capital affirms Cerulean Pharma (Nasdaq: CERU) with a Buy rating and $2.50 price target following a new collaboration with Novartis and cash infusion
http://www.streetinsider.com/Analyst+Comments/Roth+Capital+Keeps+Cerulean+Pharma+(CERU)+at+Buy+Amid+Capital+Raise,+Key+Collaboration+with+Novartis/12146027.html
Cerulean also is eligible to receive preclinical, clinical, regulatory, and sales milestones for each of the five targets of up to $233 million per target.
http://finance.yahoo.com/news/cerulean-reports-third-quarter-2016-201100941.html
During 2017, Cerulean expects to:
Report further results from the ongoing Phase 1b/2 clinical trial of CRLX101 in combination with weekly paclitaxel, in patients with platinum-resistant ovarian cancer
Report initial results from the ongoing Phase 1/2 clinical trial of CRLX101 in combination with AstraZeneca’s PARP inhibitor, LYNPARZA, in patients with advanced solid tumors
Report initial results from the ongoing Phase 1/2a clinical trial of CRLX301 using a weekly dosing schedule in patients with advanced solid tumors
$CERU Old Man Wins here :) with 1.35 in Cash and Announced five-target collaboration with Novartis received payment $5 million plus funding for five full-time equivalents and is eligible for milestone payments plus sales royalties for each target
http://files.shareholder.com/downloads/AMDA-2PIT2J/3308422877x0x912458/70869586-D91F-4F36-A76A-F9D833FB1660/CERU_News_2016_10_19_General_Releases.pdf
$MCZ CEO $WMT Walmart was a big win for us, I mean that’s a huge increase in our U.S. retail presence. $MCZ-making sure that we could launch the ARK 100 and meet the supply requirement from $WMT particularly & $GME http://seekingalpha.com/article/4019394-mad-catz-interactives-mcz-ceo-karen-mcginnis-q2-2017-results-earnings-call-transcript?source=tweet $MCZ "we expected that to start to increase October and November into the holiday season."
Holiday swing started!
$GTXI looking great! and should start trading differently crossing that 1 line
$ABIO ww as low float bio #turkey pick
https://clinicaltrials.gov/ct2/show/NCT01970501?term=GENETIC-AF&rank=1
http://stocknewsnow.com/commentary/ANEWSID14112016100002/SNNLive-Video-Interview-ARCA-biopharma-Inc-(NASDAQ-ABIO)
GENETIC-AF Trial Projected Timelines
just trading them for now, but many look to have bottomed
$REFG trades like $CNBX did before parabolic move.
$VHUB added bunch .009 thru .011
$TGD Timmins Gold Continues Strong Performance Cash Flow from Operations of $9.8 million in Q3 2016 http://finance.yahoo.com/news/timmins-gold-continues-strong-performance-002536283.html?soc_src=social-sh&soc_trk=tw
Timmins Gold EPS of $0.09
Nov. 3, 2016 3:34 AM ET|About: Timmins Gold Corp (TGD)|By: Gaurav Batavia, SA News Editor
Timmins Gold (NYSEMKT:TGD): Q3 EPS of $0.09 may not be comparable to consensus of $0.02.
Revenue of $31.21M (+17.4% Y/Y) beats by $0.21M.
$GRNH your welcome. lets get back to .16 then .20
$GRNH Here’s How Greengro Technologies Inc is Targeting Both Sides Of A Potentially Lucrative Supply Demand Arrangement In Marijuana https://www.insiderfinancial.com/heres-how-greengro-technologies-inc-otcmktsgrnh-targeting-both-sides-of-a-potentially-lucrative-supply-demand-arrangement-in-marijuana/118009/
$TGD
Canadian ones have been so beastly
I like Cali ones (as trade) with elections coming up and Cali biggest economy of states up for legalization
$CLSH I bought friday 69 and 76
$CLSH #Microfloat #PotStocks .76 very unknown and uncrowded https://t.co/xzhFf7MqFM pic.twitter.com/WCCiwVmIQq
— Beach Trades (@beach_trades) October 28, 2016
what do you like (and not ones that have already popped big)
anytime! as always caution anything OTC as they usually just momo trades, not ones to marry
$ADVT $OPMZ $FUTL $PRRE $DEQI and $IGC on big boards #Potstocks
$DEQI TY! David Tobias and 38.5% with Ovation Research
http://domainbigdata.com/deqi.info
$IGC .42 has legal cannabis strategy through the acquisition of Midtown Partners..
$IGC http://www.igcinc.us/cannabis/overview/
http://globenewswire.com/news-release/2014/12/18/692476/10112905/en/IGC-expands-legal-cannabis-strategy-through-the-acquisition-of-Midtown-Partners.html
$IGC Phytocannabinoid Patent as IGC Expands Phytocannabinoid IP Portfolio with Patent Filing for Method & Composition for Treating Seizure Disorders https://globenewswire.com/news-release/2016/06/20/849822/0/en/IGC-Expands-Phytocannabinoid-IP-Portfolio-with-Patent-Filing-for-Method-Composition-for-Treating-Seizure-Disorders.html
https://globenewswire.com/news-release/2015/07/20/753418/10142236/en/IGC-Files-Preliminary-Phytocannabinoid-Patent-For-Indication-of-Pain.html
$IGC has former US Senator Larry Pressler on board as well http://www.igcinc.us/sen-larry-pressler-1
$IGC http://www.bestmedicalmarijuanastocks.com/tag/india-globalization-capital/
$IGC has legal cannabis strategy through the acquisition of Midtown Partners..
$IGC http://www.igcinc.us/cannabis/overview/
http://globenewswire.com/news-release/2014/12/18/692476/10112905/en/IGC-expands-legal-cannabis-strategy-through-the-acquisition-of-Midtown-Partners.html
$IGC Phytocannabinoid Patent as IGC Expands Phytocannabinoid IP Portfolio with Patent Filing for Method & Composition for Treating Seizure Disorders https://globenewswire.com/news-release/2016/06/20/849822/0/en/IGC-Expands-Phytocannabinoid-IP-Portfolio-with-Patent-Filing-for-Method-Composition-for-Treating-Seizure-Disorders.html
https://globenewswire.com/news-release/2015/07/20/753418/10142236/en/IGC-Files-Preliminary-Phytocannabinoid-Patent-For-Indication-of-Pain.html
$IGC has former US Senator Larry Pressler on board as well http://www.igcinc.us/sen-larry-pressler-1
$IGC http://www.bestmedicalmarijuanastocks.com/tag/india-globalization-capital/
$BRDTD super thin after R/S http://ibreedit.com/solutions/medical-cannabis-breeders/
I keep buying little by little on bid as California pot plays will be biggest.
http://advantiscorp.com/advantis-holdings-products/
http://sports.yahoo.com/news/advantis-corp-sells-amstercans-receives-132600173.html
$ADVT bol to us!
Oh yes!
Oh really? :) dont think so